Autoinhibition of c-Abl  by Pluk, Helma et al.
Cell, Vol. 108, 247–259, January 25, 2002, Copyright 2002 by Cell Press
Autoinhibition of c-Abl
the resulting fusion protein, BCR-Abl, can have molecu-Helma Pluk,1,4 Karel Dorey,1,4
lar masses of 210, 190 (the two major forms), or 230 kDa.and Giulio Superti-Furga1,2,3
The consequences of BCR-Abl on signal transduction1 Developmental Biology Programme
pathways and the cellular effects have been studiedEuropean Molecular Biology Laboratory
extensively (Raitano et al., 1997). Dependent on the cell2 Cellzome AG
type, BCR-Abl expression results in enhanced prolifera-Meyerhofstrasse 1
tion, morphological transformation, or abrogation of69117 Heidelberg
growth factor or adhesion dependence. In general, theGermany
effects are growth stimulatory and antiapoptotic. When
forced into the nuclei of cells, however, BCR-Abl in-
duces apoptosis (Vigneri and Wang, 2001).Summary
The common feature critical for all the biological ef-
fects of BCR-Abl is its constitutively high level of tyrosineDespite years of investigation, the molecular mecha-
kinase activity derived from the catalytic domain in itsnism responsible for regulation of the c-Abl tyrosine
ABL1 moiety. The small molecular inhibitor of BCR-Ablkinase has remained elusive. We now report inhibition
catalytic activity, STI571, binds to the ATP bindingof the catalytic activity of purified c-Abl in vitro, dem-
pocket of the catalytic domain, but also interacts withonstrating that regulation is an intrinsic property of
less-conserved regulatory structural elements, affectingthe molecule. We show that the interaction of the
their function (Schindler et al., 2000). STI571 appearsN-terminal 80 residues with the rest of the protein
to target an Abl-specific inactive conformation of themediates autoregulation. This N-terminal “cap” is re-
catalytic domain, explaining its high selectivity overquired to achieve and maintain inhibition, and its loss
other tyrosine kinases. STI571 has proved to be a veryturns c-Abl into an oncogenic protein and contributes
promising therapeutic agent in clinical trials (Druker etto deregulation of BCR-Abl.
al., 1996; Thiesing et al., 2000). However, point mutations
arising in some patients appear able to confer resistanceIntroduction
to the drug (Gorre et al., 2001; McCormick 2001). It
appears particularly important to understand the mech-c-Abl is a nonreceptor tyrosine kinase ubiquitously ex-
anism responsible for natural inhibition of the cellularpressed and highly conserved in metazoan evolution.
form of the enzyme, of which we remain ignorant.c-Abl and the product of its paralog gene, Arg (ABL2),
Mutations have been identified in c-Abl, typically inresemble Src family kinases and consist of a catalytic
the SH3 domain, which unleash the catalytic activity anddomain that is preceded by a variable N-terminal region
often the oncogenic potential of the Abl protein. It isof 60 or 80 residues, an SH3 domain, and an SH2 domain
thought that these “deregulated” forms escape a critical(reviewed in Superti-Furga and Courtneidge, 1995; Van
mechanism responsible for tightly regulating the wild-Etten, 1999). In contrast to Src family kinases, c-Abl and
type protein (Pendergast et al., 1991; Mayer and Balti-Arg lack the short C-terminal regulatory tail and instead
more, 1994; reviewed in Van Etten, 1999). Several lineshave a large C-terminal portion encoded by a single
of evidence contributed to the hypothesis that a cellularexon and thus called the “last exon region.” c-Abl has
inhibitor is responsible for regulation of c-Abl. First,been implicated in processes of cell differentiation, cell
c-Abl and deregulated forms display equal levels of ac-division, cell adhesion, cell death, and stress response
tivity after precipitation or partial purification (Pender-
(Van Etten, 1999; Wang, 2000). It is found in both the
gast et al., 1991; Mayer and Baltimore, 1994; Dorey et
nucleus and cytoplasm of cells and is thought to shuttle
al., 1999). Moreover, very high levels of expression in
between the two subcellular departments, depending cells seem to exhaust regulation, as if through titration
on environmental clues (Taagepera et al., 1998). When of a cellular inhibitor (Pendergast et al., 1991). Expres-
expressed transiently in tissue culture cells, the ability sion in a heterologous system, such as the yeast Schiz-
of c-Abl to become phosphorylated on tyrosine and osaccharomyces pombe, showed no difference in activ-
phosphorylate cellular substrates is considerably weaker ity between c-Abl and deregulated forms, suggesting
than that of the natural oncogenic form BCR-Abl or of absence of a vertebrate c-Abl inhibitor in fungi (Walken-
c-Abl’s viral counterpart, v-Abl. horst et al., 1996). Other elements, such as the apparent
In humans, chronic myelogenous leukemia (CML) and difference to the regulatory mechanism of Src family
a subset of acute lymphocytic leukemia (ALL) are caus- kinases, the initially concurrent discovery of the protein-
ally linked to the presence of the Philadelphia chromo- protein interaction potential of the SH3 domain, and
some, which is the result of a translocation between the identification of a considerable number of proteins
chromosome 22 and chromosome 9. In this transloca- binding to the SH3 domain of Abl, all contributed to the
tion, sequences of the first exon of the c-Abl tyrosine wide acceptance of a cellular inhibitor theory of c-Abl
kinase gene (ABL1) are replaced by sequences from the regulation (reviewed in Van Etten, 1999; Brasher and
BCR gene. Depending on the breakpoint in the BCR gene, Van Etten, 2000).
The crystal structure of regulated c-Src (reviewed in
Sicheri and Kuriyan, 1997) prompted a mutational analy-3 Correspondence: superti@embl-heidelberg.de
4 These authors contributed equally to this work. sis that supported the possibility of c-Abl also being
Cell
248
Figure 1. Autoinhibition of c-Abl
(A) c-Abl and Abl-PP were expressed by in vitro translation in wheat germ extract. Total protein extract (left) and anti-Abl immunoprecipitates
(right) were separated by SDS-PAGE, blotted to nitrocellulose, and probed with anti-Abl and anti-phosphotyrosine antibodies.
(B) S. pombe strain SP200 was transformed with a vector expressing c-Abl, SH3-Abl, or Abl-PP under control of a thiamine repressable
promotor. Cells were lysed by boiling in SDS-sample buffer 16 (left) and 24 hr (right) after induction of protein expression by thiamine removal.
Lysates were separated by SDS-PAGE, blotted to nitrocellulose, and probed with anti-Abl and anti-phosphotyrosine antibodies.
(C) HEK293 cells were transiently transfected with SV40-driven c-Abl and Abl-PP expression plasmids. After transfection (40 hr), cells were
lysed, and Abl protein was immunopurified using covalently coupled anti-Abl antibodies. Abl and copurifying proteins were eluted by pH
shock, separated by 4%–15% gradient SDS-PAGE, and visualized by colloidal Coomassie staining (left). The identity of Abl proteins was
confirmed by mass spectrometry. Purified c-Abl and Abl-PP proteins were assayed for their catalytic activity by in vitro kinase assay using
GST-Crk as exogenous substrate. Bands were excised, and incorporated radioactivity was measured by scintillation counting. The histograph
shows the catalytic activity of purified Abl-PP compared to purified c-Abl (mean with SD of two experiments done in triplicate; right). Part of
the Abl protein used for the in vitro kinase assay was blotted and probed with anti-Abl and anti-phosphotyrosine antibodies (middle). An
autoradiograph showing an example of the incorporation of radioactivity in GST-Crk is presented.
regulated by intramolecular interactions. As in Src family sulted in the phosphorylation of c-Abl itself and of a
kinases, these would involve binding of the SH3 domain number of endogenous proteins, showing that c-Abl is
to the linker between the SH2 and catalytic domains, regulated in extracts of plant cells.
and the catalytic domain itself (Barila´ and Superti-Furga, We have previously reported that c-Abl and an SH3
1998). However, these results did not define the minimal domain deletion form of Abl were equally active and
structural requirements for c-Abl regulation, nor did they toxic in the yeast S. pombe (Walkenhorst et al., 1996).
address the in vitro regulation enigma, so that an exclu- We addressed again regulation of c-Abl in S. pombe,
sion of the existence of a cellular inhibitor responsible for this time using an inducible promoter of much weaker
the SH3 domain-dependent regulation was not possible. activity than the one used previously. In this case, SH3
Moreover, the comparison to the regulation of Src family domain-dependent regulation was observed at early in-
members lacked explanations for the absence of a regu- duction time points, as judged by a strong difference in
latory C-terminal tail in c-Abl (Barila´ and Superti-Furga, tyrosine phosphorylation of cellular proteins between
1998; Brasher and Van Etten, 2000; Van Etten, 1999). c-Abl- and Abl-PP-containing yeast cells (Figure 1B).
We present here the results of a reinvestigation of the After 24 hr, however, when more c-Abl protein had accu-
mechanism responsible for c-Abl inhibition. Our data mulated, this difference was abolished. Thus, c-Abl is
demonstrate that c-Abl is autoinhibited and does not regulated in S. pombe, but regulation is sensitive to the
require an SH3 domain-dependent cellular inhibitor. An levels of protein expression.
N-terminal “cap” region binds intramolecularly and is
required to achieve and maintain inhibition. The absence
Regulation of c-Abl In Vitroof the autoinhibitory “cap” in all BCR-Abl forms and the
We purified c-Abl and Abl-PP from transfected humaninhibitory effects upon its reintroduction suggest a new
embryonic kidney (HEK) 293 cells (Figure 1C). After amolecular basis for the oncogenic conversion of this
purification procedure that included a high-salt washlong-studied and medically important gene.
step, the Coomassie blue-stained patterns of c-Abl and
Abl-PP proteins were very similar, indicating that anyResults
protein(s) that may be responsible for the regulation of
c-Abl in vivo does not copurify in detectable amountsExpression of c-Abl in Nonvertebrate Systems
or is either too large or too small to be detected. Consti-c-Abl and Abl-PP, a deregulated form in which two pro-
tutively active Abl-PP is strongly phosphorylated on ty-lines in the putative intramolecular SH3 binding region
rosine and serine residues and thus migrates slightlyconnecting the SH2 domain to the catalytic domain are
more slowly than does c-Abl (Figure 1C, left; Dorey etmutated (P242E/P249E), were expressed in wheat germ
al., 1999). To determine the activity of the purified Ablextract. Analysis of total cellular proteins as well as of
proteins, we tested their in vitro kinase activities usingimmunoprecipitated c-Abl revealed that no tyrosine
GST-Crk as a substrate. A more than 6-fold differencephosphorylation could be detected when c-Abl is ex-
pressed (Figure 1A). However, expression of Abl-PP re- in activity between c-Abl and Abl-PP was measured
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(Figure 1C, right). We also tested a mutant in which the which is in sharp contrast to Src family kinases, where
residues N-terminal to the SH3 domain are dispensabletwo prolines in the SH2-CD linker are mutated to alanine
(Abl-P242A/P249A) to find that it was activated to a for intramolecular regulation (Koegl et al., 1995; Sicheri
and Kuriyan, 1997). Taken together, our results demon-similar extent as Abl-P242E/P249E (data not shown).
To confirm that the difference in activity involved SH3- strate that the minimal region necessary and sufficient
for the regulation of c-Abl comprises the SH3, SH2,domain-dependent regulation, we tested various other
mutants, including point mutations within the SH3 do- catalytic domain as well as the N-terminal residues.
main, v-Abl, and a mutant in which a putative intramolec-
ular salt bridge between the SH3 and catalytic domain Regulation of c-Abl by Its N Terminus
is disrupted (Abl K313E; Barila´ and Superti-Furga, 1998). To obtain functional insight into the role of the N-terminal
All deregulated forms were 7–16 times more active than region in the regulation of full-length c-Abl, we con-
wild-type c-Abl in in vitro kinase assays (data not structed additional mutants and analyzed their catalytic
shown). Similar results were also obtained with other activity in vitro and in vivo (Figure 3). As expected from
anti-Abl antibodies and other substrates (data not the results with the short Src-like form (Abl P82-K531),
shown). These results show that other cellular proteins Abl M1-D81 was strongly active also in the presence
are not necessary to maintain c-Abl in a state of catalytic of the last exon region and led to efficient phosphoryla-
inhibition. tion of cellular proteins, Abl autophosphorylation, and
Although it is unclear why it has been difficult to detect high catalytic activity in an in vitro kinase assay (Figures
such differences previously (Pendergast et al., 1991; 3B and 3C). Introduction of the deregulating mutation
Mayer and Baltimore, 1994; Dorey et al., 1999) and sev- in the SH2 catalytic domain linker in Abl M1-D81 (Abl-
eral parameters may exert an influence on c-Abl regula- PP M1-D81) had only a small further effect, suggesting
tion in vitro, we found that the nature of the divalent salt that through deletion of the N-terminal 81 residues, Abl
used in the kinase activity reaction has a profound effect becomes fully deregulated. The effect of individually
on the catalytic activity. While the use of MgCl2 at 10 deleting the first 45 residues (exon 1b, Abl M1-H45)
mM concentration allows the detection of significant or the following 36 residues (Abl E46-D81) was less
differences in catalytic activity of c-Abl versus Abl-PP, pronounced (Figures 3B and 3C). Thus, the N-terminal
the same samples assayed in the presence of 10 mM amino acids encoded by the Abl type 1b exon and the
MnCl2 resulted in no detectable difference in catalytic first part of exon 2 are both required to keep c-Abl in
activity (data not shown). its regulated state.
We also tested if the absence of this regulatory
N-terminal region activated the oncogenic potential ofMinimal Region Required for c-Abl Regulation
c-Abl. In focus-formation assays using NIH3T3-P cells, AblThe results on c-Abl regulation in vitro prompted an
E46-D81 was a reliable oncogene, reaching a transfor-investigation of the minimal part of the protein required
mation efficiency comparable to point mutations in thefor regulation. The “last exon region” has previously
SH3 domain (Table 1; Barila´ and Superti-Furga, 1998).been implicated in c-Abl regulation and represents the
binding site for several cellular proteins, including F and
G actin (Goga et al., 1993; McWhirter and Wang, 1993; The N-Terminal Region Interacts
with c-Abl In transVan Etten et al., 1994; Woodring et al., 2001). We con-
structed a deletion mutant lacking the last exon region We tested the ability of the N terminus of Abl to interact
with the rest of c-Abl. GST fusion proteins containingof c-Abl (Abl M1-K531; Figure 2A). We also engineered a
mutant lacking, additionally, the N-terminal amino acids the first exon (amino acids 1–45; GST 1b), first and part
of the second exon (amino acids 1–80; GST 1b  2),preceding the SH3 domain, known to be dispensable for
regulation of Src family kinases (Abl P82-K531; Figure 2A). and only second exon (amino acids 46–80; GST 2) of
c-Abl type 1b were prepared and used to pull downAfter transient expression in HEK293 cells, cellular
proteins were analyzed for phosphotyrosine content as transiently expressed c-Abl, Abl M1-D81, and Abl-PP
M1-D81 proteins in extracts derived from transfecteda measure of in vivo protein activity, and Abl proteins
were immunoprecipitated to test for tyrosine phosphor- HEK293 cells (Figure 4A). Since in the ABL1 gene two
alternative first exons are spliced to give rise to c-Ablylation as well as catalytic activity in vitro. Deletion of
the last exon region (Abl M1-K531) did not lead to activa- type 1a and 1b (Shtivelman et al., 1986), we also tested
similar constructs of c-Abl type 1a (amino acids 1–26;tion of Abl (Figures 2B and 2C), but the additional double
proline mutation in the SH2 catalytic domain linker (Abl- GST 1a and 1–61; GST 1a  2). All five Abl GST-fusion
proteins were able to pull down Abl M1-D81, sug-PP M1-K531) resulted in strong activation. These results
suggest that the SH3 domain-dependent regulation is gesting a direct interaction between the Abl N-terminal
amino acids and AblM1-D81 in trans. In contrast, c-Abloperational within the short form of Abl. Deletion of the
last exon region abolished the ability of Abl to phosphor- was not bound by the GST-fusion proteins, suggesting
that the binding site in c-Abl is “covered” by theylate GST-Crk but not GST-Jun, probably due to the
loss of the Crk binding site (Ren et al., 1994). N terminus in cis. Abl-PP M1-D81 bound the GST-
fusion proteins only weakly. Thus, the N-terminal regionAbl P82-K531 showed elevated tyrosine phosphoryla-
tion levels in total extracts and was highly active in appears to bind the rest of Abl in a conformation-depen-
dent manner.vitro after immunoprecipitation when compared to its
counterpart containing the normal N-terminal sequences To define the region in c-Abl to which the N-terminal
region binds, GST fusion proteins of the first exon type(Abl M1-K531; Figure 2). This suggests an involvement
of the first 81 residues of the c-Abl protein in regulation, 1a and type 1b and of the second exon were tested for their
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Figure 2. The core Element for c-Abl Regu-
lation
(A) Schematic diagram representing the dif-
ferent generated Abl proteins. The SH3, SH2,
and catalytic domains as well as the last exon
region are shown as boxes. P242 and P249
indicate the two proline residues in the SH2
catalytic domain linker that are mutated in
Abl-PP and derivatives.
(B) HEK293 cells were transiently transfected
with the indicated SV40-driven Abl expres-
sion constructs. After transfection (40 hr),
cells were lysed, and total protein extract was
analyzed by anti-Abl and anti-phosphotyro-
sine immunoblotting.
(C) Abl protein was immunoprecipitated from
total cell extract using anti-Abl antibodies,
blotted to nitrocellulose, and probed with
anti-Abl and anti-phosphotyrosine antibodies
(left). Abl immunoprecipitates were assayed
for catalytic activity by in vitro kinase assay
using GST-Jun as substrate. The histograph
shows the catalytic activity (mean with SD of
three experiments done in duplicate) of the
Abl constructs relative to Abl M1-K531.
ability to pull down transiently expressed c-Abl proteins the second exon bound preferentially to the portion of
Abl containing the SH3 and SH2 domains. Thus, different(Figure 4B), including the SH3-SH2-linker catalytic domain
portion (SH3-SH2-CD), the SH3-SH2 domains, or the cata- parts of the N-terminal region appear to bind different
parts of c-Abl, as if clamping the protein together. Be-lytic domain only (CD). The SH3-SH2-CD protein was
bound by all three GST fusion proteins. The catalytic cause of its position at the N terminus of c-Abl, we refer
to this region as the “cap.”domain was bound by first exons 1a and 1b only, while
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Figure 3. Autoinhibition of c-Abl by Its N Ter-
minus
(A) Schematic diagram representing the dif-
ferent generated Abl proteins. The SH3, SH2,
and catalytic domains as well as the last exon
region are shown as boxes. P242 and P249
indicate the two proline residues in the SH2
catalytic domain linker that are mutated in
Abl-PP and derivatives.
(B) HEK293 cells were transiently transfected
with c-Abl or the indicated Abl expression
constructs. After transfection (40 hr), cells
were lysed, and the resulting total protein ex-
tract was analyzed by anti-Abl and anti-phos-
photyrosine immunoblotting.
(C) Abl protein was immunoprecipitated from
total cell extract using anti-Abl antibodies,
blotted to nitrocellulose, and probed with
anti-Abl and anti-phosphotyrosine antibodies
(left). Abl immunoprecipitates were assayed
for catalytic activity by in vitro kinase assay
using GST-Crk as substrate. The histograph
shows the catalytic activity (mean with SD of
three experiments done in duplicate) of the
indicated Abl constructs relative to c-Abl.
Mutational Analysis of the N-Terminal Region residues, in the common second exon region. We also
mutated residues that appeared conserved between theTo understand better the nature of the interaction be-
tween the cap and the rest of Abl, we performed alanine- 1a and 1b alternative exons (Figure 5A, cap 1–6). After
transient expression in HEK293 cells, Abl proteins werescanning mutagenesis of groups of four, mostly polar,
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elements (SREs)-containing promoter and a TPA-respon-Table 1. Transformation Potential of Abl E46-D81
sive elements (TREs)-containing promoter, although to
Neo Colonies Foci in 5% CS Transformation
an extent that was slightly lower than Abl-PP (Figure(Mean  SD) (Mean  SD) Efficiency (%)
5C). While the cap 1 and the cap 6 mutants seemed to
pSLX c-Abl 5595  505 13  3 0.2 stimulate the two promoters with different efficiencies,
pSLX Abl E46-D81 2170  170 215  35 9.9
they were both clearly more active than the regulatedpSLX Abl-PP 2135  185 615  125 28.8
wild-type c-Abl control. Mutation of the cap thus elicits
NIH3T3-P cells transfected with the indicated Abl constructs in vec- the ability of Abl to stimulate signal transduction path-
tor pSLX were grown for 16 days in DMEM containing 5% calf serum ways, consistent with the ability to transform fibroblasts
to allow the formation of foci. Duplicate dishes were grown under
of the deletion mutant (Table 1). To establish a possibleneomycin selection to determine the transfection efficiency. The
correlation between the role of cap 1 and cap 6 residuestransformation efficiency was calculated by dividing the number of
foci by the number of neomycin resistant colonies of each construct. in regulation and their binding properties, GST fusion
Results shown are the averages of two experiments done in du- proteins were prepared of Abl exon 1b with the cap 1
plicate. mutation (GST 1b cap 1) and exon 2 with the cap 6
mutation (GST 2 cap 6) and used to pull down transiently
expressed SH3-SH2-CD and CD Abl proteins from
HEK293 cell extracts (Figure 5D). Mutation of both capimmunoprecipitated to test for tyrosine phosphorylation
1 and cap 6 residues prevented binding to the SH3-content as well as for catalytic activity in vitro. The cap
SH2-CD protein, and the relatively strong binding of1 and cap 6 mutants were phosphorylated and exhibited
exon 1b to the catalytic domain was strongly reducedan increased catalytic activity (Figure 5B). To test the
by mutation of cap 1 residues. These results show thatability of the cap 1 and cap 6 mutants to stimulate cellular
both conserved residues of exon 1 and residues of exonsignal transduction and elicit transcriptional responses in
2 are required for the binding to Abl and its regulation.the nucleus, we cotransfected various Abl-expressing
plasmids with different growth-sensitive promoters driv-
ing the luciferase gene (Alexandropoulos and Baltimore, The N-Terminal Region Is Required to Maintain
the Regulated State1996; Raitano et al., 1995; Renshaw et al., 1996; Barila´
and Superti-Furga, 1998). To standardize the experiment The N-terminal region may only be required to assemble
the regulatory apparatus, possibly during folding, andfor transfectional efficiency and extract preparation, we
used the ubiquitin promoter driving the Renilla lucifer- then becomes dispensable. Alternatively, the N-ter-
minal region may target c-Abl to particular subcellularase. Expression of c-Abl missing the cap region led
to a significant stimulation of both a serum-responsive sites and only indirectly affect c-Abl regulation. To rule
Figure 4. In Vitro Binding of the N-Terminal
Region to Abl Protein
(A) c-Abl, Abl M1-D81, or Abl-PP M1-D81
were expressed in HEK293 cells. Cell lysates
were incubated with the indicated GST fusion
proteins bound to glutathion-Sepharose
beads. Adsorbates were analyzed by SDS-
PAGE followed by anti-Abl immunoblotting
(left). Inputs are shown for Abl (right); identical
amounts of GST fusion proteins were used for
each pull-down as quantified by Coomassie
blue staining (data not shown).
(B) HA-tagged pieces of Abl were expressed
in HEK293 cells. Cell lysates were incubated
with the indicated GST fusion proteins, as
described in (A). Adsorbates were analyzed
by SDS-PAGE, followed by anti-HA immu-
noblotting.
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Figure 5. Mutagenesis Analysis of the N-Terminal Cap
(A) Alignment of the c-Abl type 1a and 1b N-terminal regions. Indicated are the residues (groups of four residues in a row) that are mutated
to alanine for the different cap mutants (cap 1–6).
(B) Abl cap mutant proteins and the indicated Abl constructs were transiently expressed in HEK293 cells. Anti-Abl immunoprecipitates were
analyzed by anti-Abl and anti-phosphotyrosine immunoblotting (left) and assayed for catalytic activity by in vitro kinase assay using GST-Crk
as substrate (right). The histograph shows the fold of activation of the different constructs compared to c-Abl (mean with SD of two experiments
done in duplicate).
(C) Transcriptional assay: HEK293 cells were transfected as indicated together with a luciferase reporter plasmid under the control of a
promoter containing serum-responsive elements (Alexandropoulos and Baltimore, 1996) or TPA-responsive elements pAP1 (Promega). After
transfection (24 hr), extracts were assayed for luciferase activity after standardization. The histogram shows the mean of two independent
experiments done in duplicate, with standard deviations.
(D) HA-tagged Abl protein pieces (SH3-SH2-CD and CD) were expressed in HEK293 cells. Cell lysates were incubated with the indicated GST
fusion proteins bound to glutathion-Sepharose beads. Adsorbates were analyzed by SDS-PAGE, followed by anti-HA immunoblotting.
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Figure 6. Role of the N-Terminal Cap of c-Abl
(A) Schematic diagram showing the se-
quence of the N terminus of c-Abl. The SH3,
SH2, and catalytic domains as well as the last
exon region are represented by boxes. The
amino acid sequence of the N terminus of
the c-Abl type 1b protein is shown. The bold
arrow indicates the beginning of thea strand
of the SH3 domain, the engineered TEV cleav-
age site is marked in black, and the arrow-
head indicates the exact position of cleavage
by TEV protease.
(B) Abl-TEV and indicated constructs were
expressed in HEK293 cells and immunopre-
cipitated with anti-Abl antibodies. Immune-
complexes were incubated without () or
with () TEV protease, separated by SDS-
PAGE, blotted to nitrocellulose, and probed
with anti-Abl antibodies (top). Immunecom-
plexes were assayed for catalytic activity by
in vitro kinase assay using GST-Crk as sub-
strate (bottom). The histograph shows the
fold of activation induced by TEV protease
(mean with SD of three independent experi-
ments). This was calculated by dividing the
catalytic activity of Abl protein after TEV treat-
ment by the catalytic activity without TEV in-
cubation.
(C) Model of the three-dimensional arrange-
ment of c-Abl including the N-terminal regula-
tory cap based on known structures of the
SH3 domain, the SH2 domain, and the cata-
lytic domain of Abl and on regulated Src. The
N-terminal cap is represented as a rod struc-
ture that may bind to the north face of Abl,
thus stabilizing the regulated structure in
which the SH3 domain is bound via the SH2
catalytic domain linker to the catalytic do-
main. The arrowhead indicates the position
of the engineered TEV cleavage site.
out these possibilities, we took advantage of the pres- residues required to engineer the TEV site did not affect
c-Abl regulation (Figure 6B). We transfected HEK293ence of residues resembling the cleavage site for the
highly specific tobacco etch virus (TEV) protease cells with Abl-TEV as well as with control Abl constructs.
Abl proteins were immunoprecipitated and treated orroughly at the boundary between the N terminus and
the SH3 domain. We engineered a perfect TEV site by not with TEV protease. TEV treatment caused the ap-
pearance of a faster-migrating form of Abl-TEV but notmutating four residues to obtain Abl-TEV. The TEV cleav-
age would occur 7 residues upstream of Phe85, repre- of c-Abl (Figure 6B). Kinase assays performed in parallel
revealed a TEV-dependent increase in catalytic activitysenting the beginning of theA strand of the SH3 domain
(Figure 6A; Musacchio et al., 1994). Mutation of the four only in Abl-TEV and not in c-Abl or Abl M1-D81 (Figure
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6B). The extensive washes of the immunoprecipitated
protein likely removed the cleaved N-terminal portion.
Thus, cleaving the N-terminal 77 residues of c-Abl in
vitro leads to its activation. We conclude that the
N-terminal residues are necessary to maintain the inhib-
ited state of c-Abl and that they have a critical role in
its regulation.
The N-Terminal Region Inhibits Abl In Vitro
and Restores Regulation of BCR-Abl
To test whether the interactions of the cap are sufficient
to restore Abl regulation in vitro, we purified a GST fusion
protein of the N-terminal region of type 1b Abl (GST
1b  2) and incubated it with immunoprecipitated Abl
M1-D81 and with its counterpart bearing the additional
PP mutation in the linker (Figure 7A). While the GST
control protein had no effect on catalytic activity, GST
1b  2 inhibited Abl M1-D81 activity roughly 40%. A
significant but reduced level of inhibition was achieved
also with Abl-PP M1-D81. This result could indicate a
potential direct effect on Abl’s catalytic activity, rather
than on mere “regulation,” and could also reflect the
residual binding of GST 1b  2 to Abl-PP M1-D81
observed previously (Figure 4).
BCR-Abl fusion proteins invariably miss the first exon
sequences. If Abl’s cap region is so powerful that it
can reregulate even active forms of Abl (such as Abl
M1-D81), the missing first exon may restore regulation
of BCR-Abl if reintroduced in the molecule between the
BCR sequences and the beginning of the second exon
(BCR-cap-Abl; Figure 7B). In parallel to such constructs,
we also tested versions in which the coiled-coil region
of BCR-Abl, critically involved in dimerization, is missing
(CC BCR-cap-Abl; McWhirter et al., 1993). Expression
in HEK293 cells was equally efficient for all BCR-Abl
forms (data not shown). Immunoprecipitation was less
efficient for BCR-Abl proteins than for the forms bearing
the deletion of the coiled-coil region (Figure 7B, top).
To monitor BCR-Abl’s activity in the cell, we chose to
use antibodies specific for tyrosine 412 in the activation
loop, likely to reflect the state of activity better than anti-
phosphotyrosine, since BCR-Abl is tyrosine phosphory-
lated also at other sites that may not be directly depen-
dent on catalytic activity (Pendergast et al., 1993a,
1993b). As expected, if compared to the levels of immu-
noprecipitated protein, the forms bearing the coiled-coil
deletion were less phosphorylated at Tyr412, reflecting
the importance of dimerization for BCR-Abl activity (Fig-
1b  2), dialyzed against kinase assay buffer, and subsequently
assayed for catalytic activity by in vitro kinase assay using GST-
Crk as substrate. The histograph shows the percentage of inhibition
(mean with SD of three experiments done in duplicate).
(B) HEK293 cells were transfected with the indicated constructs.
After an immunoprecipitation using anti-Abl antibodies, the immune-
complexes were analyzed by Western blot anti-Abl (top) or anti-
p412 (bottom).
(C) Effect of the cap on the catalytic activity of BCR-Abl orCC BCR-
Figure 7. Inhibition of Catalytic Activity by the N-Terminal Cap Abl tested by in vitro kinase assay using GST-Crk as a substrate. The
(A) Abl M1-D81 and Abl-PP M1-D81 were transiently expressed activity of BCR-Abl andCC BCR-Abl is set to 100%; the histograph
in HEK293 cells and immunoprecipitated using anti-Abl antibodies. shows the variation of catalytic activity when the cap is restored in
Immunecomplexes were incubated for 2 hr with kinase assay buffer BCR-Abl or in CC BCR-Abl (mean of two independent experiments
() or with equal amounts of GST fusion protein (GST or GST Abl done in duplicate with SD).
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ure 7B; McWhirter et al., 1993; Smith and Van Etten, tion of c-Abl (Franz et al., 1989; Jackson and Baltimore,
1989; Wang, 1988), but the results were not sufficiently2001). Introduction of the first exon sequences did not
conclusive, and attention focused on the discovery andhave a measurable effect on Tyr412 phosphorylation of
function of the adjacent SH3 domain, obscuring the roleBCR-Abl but caused a dramatic reduction in the activity
of the extreme N terminus of c-Abl.of BCR-Abl bearing the coiled-coil deletion. To test
We suggest a novel model according to which c-Abl iswhether this decrease in activation loop phosphoryla-
regulated by a set of intramolecular interactions (Figuretion also reflected a reduced catalytic activity in vitro,
6C). While Src family kinases have an interaction of theirwe performed kinase assays with the different immuno-
tail with their own SH2 domain that contributes criticallyprecipitated BCR-Abl proteins. The cap-bearing version
to maintenance of the SH3 domain-dependent regula-of CC BCR-Abl showed about 25% of the activity of
tion, c-Abl has an N-terminal cap that serves an analo-its normal counterpart (Figure 7C). Together, these data
gous function. This cap appears to bind at several re-show that the first exon region is capable of restoring
gions “across” the molecule and stabilize the regulated,regulation to a dimerization-deficient BCR-Abl, confirm
inhibited conformation. According to our data, the “KV/the dominant features of dimerization in overriding the
LV/LG” motif (see cap 1 region in Figure 5A), which isnatural regulation of Abl, and suggest that loss of the
common to both type 1a and 1b exons and required forfirst exon may contribute to deregulation of BCR-Abl.
binding, must undergo relatively strong interactions with
the catalytic domain. The first part of the common sec-Discussion
ond exon does not interact with the catalytic domain
but interacts with the SH3 and/or SH2 domains. FigureThe data presented here demonstrate regulation of puri-
6C shows the cap as if binding to the “north face” merelyfied c-Abl in vitro as well as regulation in nonanimal
for graphic convenience. In fact, because the two re-expression systems. Regulation of c-Abl activity is thus
gions known to be critical for binding (the cap 1 andan intrinsic property and does not require a particular
cap 6 residues) are spaced differently in the 1a and 1bcellular inhibitor. An intramolecular sandwich involving
forms of Abl, some of the 19 additional residues of thethe SH3 domain, the linker between the SH2 and cata-
type 1b cap may “loop out” from whatever is the minimallytic domain, and the catalytic domain itself has been
“bridge” from the SH3 to the catalytic domain.proposed to regulate the activity of c-Abl as it does in
The experiment with the engineered form of c-Abl inSrc family kinases (Barila´ and Superti-Furga, 1998). In
which the presence of the N-terminal region is removedSrc family kinases, however, the assistance of the
in vitro, has shown that the N terminus is required toC-terminal tail region is essential. What structure in c-Abl
maintain and not merely to assemble the regulated con-substitutes for the C-terminal tail of Src? The last exon
formation. This is also confirmed by the ability of capregion of c-Abl bears nuclear import and nuclear export
sequences to inhibit cap-less Abl in vitro. This mecha-signals on top of binding sites for a variety of cellular
nism may be exploited by cellular proteins that inhibitproteins including actin, Crk, Nck, and p53. There is
c-Abl in trans.genetic evidence that it plays a role in the regulation of
In general, cellular proteins may either inhibit or acti-
c-Abl in cells (Goga et al., 1993; Woodring et al., 2001).
vate c-Abl by favoring or displacing any of the several
We show, however, that the last exon region of c-Abl
critical intramolecular interactions. For example, numer-
is totally dispensable for the SH3 domain-dependent
ous proteins bind the Abl SH3 domain (reviewed in Van
regulation of catalytic activity as defined here and mea- Etten, 1999). Moreover, an interdependence of the intra-
sured in vitro. molecular interactions and catalytic activity, as in Src
If the last exon region is dispensable, what is minimally family kinases, seems highly probable (Gonfloni et al.,
required? In addition to the SH3, SH2, and catalytic 2000). In this view, phosphorylation of the activation
domains, the Src-like “core,” we found an unexpected loop with its conformational effects on the catalytic do-
critical role for the first 81 residues of the c-Abl protein. main and the SH3 and cap-mediated inhibitory intramo-
In this respect, c-Abl differs to Src family kinases, where lecular interactions antagonize each other. The degree
residues N-terminal to the SH3 domain are dispensable of catalytic activity and the degree of SH3 domain avail-
for intramolecular regulation (Koegl et al., 1995; Sicheri ability are the net result of these opposing forces. In
and Kuriyan, 1997). An immediate suggestion concern- fact, the PTP-PEST tyrosine phosphatase, dephosphor-
ing a regulatory role of the N terminus comes from the ylating the activation loop, acts as an inhibitor of c-Abl
fact that in the ABL1 gene, two alternative first exons (Cong et al., 2000), while Src family kinases and Abl itself
are spliced to give rise to c-Abl type 1a or 1b (Shtivelman act as activators by causing phosphorylation (Plattner et
et al., 1986). c-Abl 1a is 19 amino acids shorter, is spliced al., 1999; Brasher and Van Etten, 2000; Dorey et al.,
much less frequently and does not include a myristoyla- 2001). We have recently found that c-Abl is phosphory-
tion signal. There is no evidence in the literature that lated at Ser94 in the RT loop of the SH3 domain when
would indicate different levels of activity between the cotransfected with an active form of Src (K.D., unpub-
two forms. Transgenes encoding both type I and type lished data). While the effects of this phosphorylation
IV c-Abl proteins rescue the lethality of c-abl mutant event and the kinase responsible are not yet known, it
mice (Hardin et al., 1996). Our attempts to express Abl is possible that this or other modifications can modulate
bearing the type 1a exon in cells failed, consistent with binding of the cap region.
the report of others (Van Etten, 1999), but when trans- We believe that the cap represents the missing link
lated in reticulocyte lysates, type 1a Abl is regulated as in c-Abl’s intramolecular regulation. The first exon region
well as type 1b (K.D., unpublished data). Early reports is lacking in all of the different fusion proteins formed
with BCR or TEL resulting from chromosomal transloca-had addressed the role of the N terminus in the regula-
Autoinhibition of c-Abl
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tion (10 min at 13,000 rpm). Abl protein was immunoprecipitatedtions and also in v-Abl. The dimerization properties of
from total cell lysates in IP buffer using anti-Abl antibody (Ab-3,BCR and TEL are thought to induce crossphosphoryla-
Oncogene Science or K12, Santa Cruz). Immune complexes weretion and activation of the catalytic domains by induced
recovered using protein G-Sepharose beads, assayed for Abl cata-
proximity and thus represent critical “gain-of-function” lytic activity, and analyzed by SDS-PAGE followed by anti-Abl (Ab-3
alterations of c-Abl (Golub et al., 1996; McWhirter et al., or K12) and anti-phosphotyrosine (4G10, Upstate Biotechnology)
immunoblotting. Anti-p412 antibodies that specifically recognize Abl1993; Smith and Van Etten, 2001). Moreover, signaling
when phosphorylated in the activation loop were a kind gift fromproperties in the BCR portion of BCR-Abl are known
Dr J. Wu (Cell Signaling Technology [CST], Beverly, MA).to be critical for transformation (reviewed in Sawyers,
1992). Our data suggest that the absence of the N-ter-
Large-Scale Purification of Abl Proteinminal cap in BCR-Abl (and in TEL-Abl and v-Abl) repre-
c-Abl and Abl-PP protein were expressed by transient transfection
sents a “loss-of-function” alteration that contributes to in HEK293 cells. After transfection (40 hr), cells were lysed in IP
the acquisition of constitutive tyrosine kinase activity buffer and insoluble material was removed by centrifugation at
100,000  g for 1 hr. Cell lysates were incubated with anti-Ablin these oncogenic forms. Thus, the cap of c-Abl may
antibodies (Ab-3, Oncogene Science) covalently coupled to proteinrepresent what the C-terminal tail represents for c-Src.
G-Sepharose beads. Beads were washed with IP buffer followedA crystal structure of c-Abl including the cap will be
by phosphate buffer (50 mM NaPhosphate [pH 6.3], 0.1% Triton-essential to elucidate the precise molecular mechanism
X100, 500 mM NaCl). Bound proteins were used for Abl kinase assay
of regulation, and future work will address how the cap directly or eluted by pH shock (50 mM glycine [pH 2.5], 0.1% Triton-
may modulate c-Abl differentially in the different splice X100, 150 mM NaCl) and run on a 4%–15% gradient SDS-PAGE gel
(Biorad). Abl and copurifying proteins were detected by brilliant bluevariants and in the context of cellular signaling networks.
colloidal Coomassie staining (Sigma).
Experimental Procedures
Abl Kinase Assay
The catalytic activity of purified Abl protein bound to protein G-Seph-DNA Constructs
arose beads was determined as follows. Beads were washed threepSGT vector and pSGT-Abl constructs were previously described
times with IP buffer, two times with IP buffer without NaCl, and two(Barila´ and Superti-Furga, 1998). Abl M1-K531, Abl-PP M1-K531,
times with kinase assay buffer (20 mM Tris-HCl [pH 7.5], 10 mMand Abl P82-K531 were obtained by PCR with c-Abl type 1b as
MgCl2, 1 mM DTT). Twenty microliters kinase assay mix (1 g GST-template and subcloned in pSGT vector. For preparation of AblM1-
Crk121-226 [Dorey et al., 1999], 0.5 l [-32P]ATP [Amersham], 0.1H45, Abl E46-D81, Abl M1-D81, and Abl-PP M1-D81, pSGT-c-
mM ATP in kinase assay buffer) was added, and the mixture wasAbl or pSGT-Abl-PP were digested with EcoRI and KpnI, and the
incubated at room temperature for 10 and 20 min. The kinase reac-released N-terminal fragment was replaced by a PCR product con-
tion was stopped by adding SDS sample buffer and was analyzedtaining the desired deletion. Point mutations and cap mutants (cap
by SDS-PAGE. Quantification of the reaction was done by cutting1–6) were obtained using the quick-change site-directed mutagene-
the desired bands from gel followed by liquid scintillation countingsis kit (Stratagene) and pSGT-c-Abl type 1b DNA as template. All
and/or phosphoimager analysis. For the in vitro inhibition of Abl,mutagenesis constructs were confirmed by sequencing. The SH3-
GST or GST 1b  2 protein were bacterially expressed, purified,SH2-CD (N80-K531), SH3-SH2 (N80-P235), or CD (D252-K531) Abl
and dialysed against kinase assay buffer. Equal quantities of purifiedprotein parts were amplified using hAbl as a template and subcloned
proteins were added directly to the kinase assay mixture, samplesinto a CMV driven vector containing a HA tag (described in Barila´
were incubated for 2 hr at 4	C, and then assayed as above.et al., 2000).
The p210 BCR-Abl is a kind gift from Owen Witte. pSGT BCR-Abl
and pSGT CC BCR-Abl have been reconstituted by amplifying, Focus Formation Assay
respectively, M1-F1059 and L61-F1059. The resulting BCR-Abl frag- Abl DNAs were subcloned from pSGT to pSLX vector (Renshaw et
ments were digested EcoRI/Kpn I (a unique internal site in Abl) and al., 1995) by BamHI digestion. Focus formation assay was performed
subcloned into pSGT hAbl backbone. To generate pSGT BCR-cap- in NIH3T3-P cells (Renshaw et al., 1992) using 0.5 g of pSLX-
Abl and pSGT CC BCR-cap-Abl, BCR (M1-S927) orCC BCR (L61- Abl DNA essentially as described (Barila´ and Superti-Furga, 1998;
S927) have been amplified using p210 as a template. The PCR Renshaw et al., 1995). Percentage of foci was calculated by dividing
products were digested EcoRI/NotI and subcloned into pSGT hAbl. the number of foci by the number of neomycin-resistant colonies
All PCR products were sequenced. of each construct.
Expression of Abl in Wheat Germ Extract and S. pombe Transcription Assay
c-Abl and Abl-PP RNA were prepared as described (Dorey et al., HEK293 cells 70% confluent in 6 cm dishes were transfected with
1999) and used for expression of protein in wheat germ extract using 0.01 g of Ubi-Renilla vector for normalization of the luciferase
a commercial translation system (Promega). pSGT-c-Abl,SH3-Abl, assay (a kind gift of Carsten Weiss), 2 g of SRE-luciferase plasmid
and Abl-PP (Barila´ and Superti-Furga, 1998) were subcloned to the (Alexandropoulos and Baltimore, 1996) or pAP1-luciferase (Pro-
yeast pRWP vector, a derivative of pRSP (Superti-Furga et al., 1993) mega), and the different constructs as indicated. After 24 hr, cells
containing a mutation of the nmt1 promoter, making it approximately were lysed in 300 l of passive lysis buffer (Promega). Five microli-
ten times weaker (Basi et al., 1993), and transformed to S. pombe ters of extract was used for the luciferase assay, performed under
strain SP200 (Superti-Furga et al., 1993). Expression of Abl protein standard conditions.
was induced by removal of thiamine as described (Walkenhorst et
al., 1996), and yeast cellular protein extracts were made by boiling In Vitro Binding Assay
pelleted yeast cells in SDS sample buffer 16 and 24 hr after induction. DNA fragments corresponding to c-Abl amino acids, M1-H45 (1st
exon type 1b), E46-N80 (beginning of the 2nd exon until the start
of the SH3 domain), and M1-N80 (1st exon type 1b  2nd exon)Transfection and Immunoprecipitation
HEK293 cells were cultured in Dulbecco’s Modified Eagle’s Medium were amplified by PCR using c-Abl type 1b as template. M1-E26
(1st exon type 1a) and M1-N61 (1st exon type 1a  2nd exon) weresupplemented with 10% fetal calf serum. Cells were transfected
with pSGT-Abl DNAs using the calcium phosphate method. After generated using c-Abl type 1a as template. All PCR products were
cloned in pGEX-2T vector. Bacterially produced Abl GST fusiontransfection (40 hr), cells were lysed in IP buffer (50 mM Tris-HCl
[pH 7.5], 150 mM NaCl, 1% NP-40, 5 mM EDTA, 5 mM EGTA, 25 proteins were prebound to glutathion-Sepharose beads and incu-
bated with 2 mg of HEK293 cell lysate containing c-Abl, Abl M1-mM NaF, 1 mM orthovanadate, 1 mM PMSF, 10 g/ml TPCK, 5 g/
ml TLCK, 1 g/ml leupeptin, 1 g/ml aprotinin, 10 g/ml soybean D81, Abl-PP M1-D81, or HA-tagged Abl protein parts (SH3-SH2-
CD, SH3-SH2, or CD) for 3 hr at 4	C. Bound proteins were analyzedtrypsin inhibitor), and insoluble material was removed by centrifuga-
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by SDS-PAGE, followed by anti-Abl or anti-HA (12CA5, Boehringer Rosenberg, N., and Witte, O.N. (1993). Oncogenic activation of c-Abl
by mutation within its last exon. Mol. Cell. Biol. 13, 4967–4975.Mannheim) immunoblotting.
Golub, T.R., Goga, A., Barker, G.F., Afar, D.E.H., McLaughlin, J.,
TEV Cleavage of Abl Protein Bohlander, S.K., Rowley, J.D., Witte, O.N., and Gilliland, D.G. (1996).
An artificial TEV cleavage site was engineered in c-Abl just before Oligomerization of the Abl tyrosine kinase by the Ets protein TEL in
the SH3 domain using the quick-change site-directed mutagenesis human leukemia. Mol. Cell. Biol. 16, 4107–4116.
kit (Stratagene). c-Abl amino acids 74–77 (LAGP) were replaced by Gonfloni, S., Weijland, A., Kretzschmar, J., and Superti-Furga, G.
YFQG, introducing a perfect TEV consensus site, giving rise to Abl- (2000). Crosstalk between the catalytic and regulatory domains
TEV. After expression of Abl-TEV in HEK293 cells and immunopre- allows bidirectional regulation of Src. Nat. Struct. Biol. 7, 281–286.
cipitation using anti-Abl antibodies (Ab-3, Oncogene Science), the
Gorre, M.E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R.,immune complexes bound to protein G-Sepharose beads were incu-
Rao, P.N., and Sawyers, C. (2001). Clinical resistance to STI-571bated for 2 hr at 16	C in 10 mM Tris (pH 8.0), 100 mM NaCl, 0.1%
cancer therapy caused by BCR-ABL gene mutation or amplification.Igepal, 0.5 mM EDTA with or without 10 units of TEV enzyme
Science 293, 876–880.(GIBCO). Subsequently, beads were processed as described for Abl
Hardin, J.D., Boast, S., Mendelsohn, M., de los Santos, K., and Goff,kinase assay.
S.P. (1996). Transgenes encoding both type I and type IV c-abl
proteins rescue the lethality of c-abl mutant mice. Oncogene 12,Acknowledgments
2669–2677.
We would like to thank J. Kretzschmar for expert technical assis- Jackson, P., and Baltimore, D. (1989). N-terminal mutations activate
tance, J.Y. Wang, K. Smith, R. Van Etten, J. Wu, A. Merino, and O. the leukemogenic potential of the myristylated form of c-abl. EMBO
Witte for various reagents and suggestions, J.R. Engen for preparing J. 8, 449–456.
the Abl model, S.A. Courtneidge for suggesting the wheat germ Koegl, M., Courtneidge, S.A., and Superti-Furga, G. (1995). Struc-
expression experiment several years ago, and M. Saraste for urging tural requirements for the efficient regulation of the Src protein
us to define the minimal requirements for regulation in vitro. We tyrosine kinase by Csk. Oncogene 11, 2317–2329.
thank R. Mangano and O. Hantschel for help throughout the work.
Mayer, B.J., and Baltimore, D. (1994). Mutagenic analysis of the
M. Way, M. Saraste, B. Nagar, A. Nebreda, R. Klein, and all members
roles of SH2 and SH3 domains in regulation of the Abl tyrosine
of the laboratory are thanked for critical reading of the manuscript.
kinase. Mol. Cell. Biol. 14, 2883–2894.
H.P. is supported by a European Community fellowship. This work
McCormick, F. (2001). New-age drug meets resistance. Nature 412,is dedicated to the memory of Matti Saraste.
281–282.
McWhirter, J.R., and Wang, J.Y. (1993). An actin-binding functionReceived May 29, 2001; revised January 9, 2002.
contributes to transformation by the Bcr-Abl oncoprotein of Phila-
delphia chromosome-positive human leukemias. EMBO J. 12, 1533–References
1546.
Alexandropoulos, K., and Baltimore, D. (1996). Coordinate activation McWhirter, J.R., Galasso, D.L., and Wang, J.Y. (1993). A coiled-
of c-Src by SH3- and SH2-binding sites on a novel p130Cas-related coil oligomerization domain of Bcr is essential for the transforming
protein, Sin. Genes Dev. 10, 1341–1355. function of Bcr-Abl oncoproteins. Mol. Cell. Biol. 13, 7587–7595.
Barila´, D., and Superti-Furga, G. (1998). An intramolecular SH3- Musacchio, A., Saraste, M., and Wilmanns, M. (1994). High-resolu-
domain interaction regulates c-Abl activity. Nat. Genet. 18, 280–282. tion crystal structures of tyrosine kinase SH3 domains complexed
with proline-rich peptides. Nat. Struct. Biol. 1, 546–551.Barila´, D., Mangano, R., Gonfloni, S., Kretzschmar, J., Moro, M.,
Bohmann, D., and Superti-Furga, G. (2000). A nuclear tyrosine phos- Pendergast, A.M., Muller, A.J., Havlik, M.E., Clark, R., McCormick,
phorylation circuit: c-Jun as an activator and substrate of c-Abl and F., and Witte, O.N. (1991). Evidence for regulation of the human ABL
JNK. EMBO J. 19, 273–281. tyrosine kinase by a cellular inhibitor. Proc. Natl. Acad. Sci. USA 88,
5927–5931.Basi, G., Schmid, E., and Maundrell, K. (1993). TATA box mutations
in the Schizosaccharomyces pombe nmt1 promoter affect transcrip- Pendergast, A.M., Gishizky, M.L., Havlik, M.H., and Witte, O.N.
tion efficiency but not the transcription start point or thiamine re- (1993a). SH1 domain autophosphorylation of P210 BCR/ABL is re-
pressibility. Gene 123, 131–136. quired for transformation but not growth factor independence. Mol.
Cell. Biol. 13, 1728–1736.Brasher, B.B., and Van Etten, R.A. (2000). c-Abl has high intrinsic
tyrosine kinase activity that is stimulated by mutation of the src Pendergast, A.M., Quilliam, L.A., Cripe, L.D., Bassing, C.H., Dai,
homology 3 domain and by autophosphorylation at two distinct Z., Li, N., Batzer, A., Rabun, K.M., Der, C.J., Schlessinger, J., and
regulatory tyrosines. J. Biol. Chem. 275, 35631–35637. Gishizky, M.L. (1993b). BCR-ABL-induced oncogenesis is mediated
by direct interaction with the SH2 domain of the GRB-2 adaptorCong, F., Spencer, S., Cote, J.F., Wu, Y., Tremblay, M.L., Lasky,
protein. Cell 75, 175–185.L.A., and Goff, S.P. (2000). Cytoskeletal protein PSTPIP1 directs
the PEST-type protein tyrosine phosphatase to the c-Abl kinase to Plattner, R., Kadlec, L., DeMali, K.A., Kazlauskas, A., and Pender-
mediate Abl dephosphorylation. Mol. Cell 6, 1413–1423. gast, A.M. (1999). c-Abl is activated by growth factors and Src family
kinases and has a role in the cellular response to PDGF. Genes Dev.Dorey, K., Barila´, D., Gavin, A.C., Nebreda, A.R., and Superti-Furga,
13, 2400–2411.G. (1999). Regulation of human c-Abl tyrosine kinase activity in
Xenopus oocytes and acceleration of progesterone-induced G2/M Raitano, A.B., Halpern, J.R., Hambuch, T.M., and Sawyers, C.L.
transition by oncogenic forms. Biol. Chem. 380, 223–230. (1995). The Bcr-Abl leukemia oncogene activates Jun kinase and
requires Jun for transformation. Proc. Natl. Acad. Sci. USA 92,Dorey, K., Engen, J.R., Kretzchmar, J., Wilm, M., Neubauer, G.,
11746–11750.Schindler, T., and Superti-Furga, G. (2001). Phosphorylation and
structure-based functional studies reveal multiple roles for the acti- Raitano, A.B., Whang, Y.E., and Sawyers, C.L. (1997). Signal trans-
vation loop of the c-Abl tyrosine kinase. Oncogene 20, 8075–8084. duction by wild-type and leukemogenic Abl proteins. Biochim. Bio-
phys. Acta 1333, F201–F216.Druker, B.J., Tamura, S., Buchdunger, E., Ohno, S., Segal, G.M.,
Fannin, S., Zimmerman, J., and Lydon, N.B. (1996). Effects of a Ren, R., Ye, Z.-S., and Baltimore, D. (1994). Abl protein-tyrosine
selective inhibitor of the Abl tyrosine kinase on the growth of Bcr- kinase selects the Crk adapter as a substrate using SH3-binding
Abl positive cells. Nat. Med. 2, 561–566. sites. Genes Dev. 8, 783–795.
Franz, W.M., Berger, P., and Wang, J.Y.J. (1989). Deletion of an Renshaw, M.W., Kipreos, E., Albrecht, M.R., and Wang, J.Y.J. (1992).
N-terminal regulatory domain of the c-Abl tyrosine kinase activates Oncogenic v-Abl tyrosine kinase can inhibit or stimulate growth,
its oncogenic potential. EMBO J. 8, 137–147. depending on the cell context. EMBO J. 11, 3941–3951.
Renshaw, M.W., McWhirter, J.R., and Wang, J.Y.J. (1995). The hu-Goga, A., McLaughlin, J., Pendergast, A.M., Parmar, K., Muller, A.,
Autoinhibition of c-Abl
259
man leukemia oncogene bcr-abl abrogates the anchorage require-
ment but not the growth factor requirement for proliferation. Mol.
Cell. Biol. 15, 1286–1293.
Renshaw, M.W., Lea-Chou, E., and Wang, J.Y. (1996). Rac is required
for v-Abl tyrosine kinase to activate mitogenesis. Curr. Biol. 6, 76–83.
Sawyers, C.L. (1992). The bcr-abl gene in chronic myelogenous
leukemia. Cancer Surv. 15, 37–51.
Schindler, T., Bornmann, W., Pellicena, P., Miller, W.T., Clarkson, B.,
and Kuriyan, J. (2000). Structural mechanism for STI-571 inhibition of
abelson tyrosine kinase. Science 289, 1938–1942.
Shtivelman, E., Lifshitz, B., Gale, R.P., Roe, B.A., and Canani, E.
(1986). Alternative splicing of RNAs transcribed from the human abl
gene and from the bcr-abl fused gene. Cell 47, 277–284.
Sicheri, F., and Kuriyan, J. (1997). Structures of Src-family tyrosine
kinases. Curr. Opin. Struct. Biol. 7, 777–785.
Smith, K.M., and Van Etten, R.A. (2001). Activation of c-Abl kinase
activity and transformation by a chemical inducer of dimerization.
J. Biol. Chem. 276, 24372–24379.
Superti-Furga, G., and Courtneidge, S.A. (1995). Structure-function
relationships in Src family and related protein tyrosine kinases. Bi-
oessays 17, 321–330.
Superti-Furga, G., Fumagalli, S., Koegl, M., Courtneidge, S.A., and
Draetta, G. (1993). Csk inhibition of Src activity requires both the
SH2 and SH3 domains of Src. EMBO J. 12, 2625–2634.
Taagepera, S., McDonald, D., Loeb, J.E., Whitaker, L.L., McElroy,
A.K., Wang, J.Y., and Hope, T.J. (1998). Nuclear-cytoplasmic shut-
tling of C-ABL tyrosine kinase. Proc. Natl. Acad. Sci. USA 95, 7457–
7462.
Thiesing, J.T., Ohno-Jones, S., Kolibaba, K.S., and Druker, B.J.
(2000). Efficacy of STI571, an abl tyrosine kinase inhibitor, in con-
junction with other antileukemic agents against bcr-abl-positive
cells. Blood 96, 3195–3199.
Van Etten, R.A. (1999). Cycling, stressed-out and nervous: cellular
functions of c-Abl. Trends Cell Biol. 9, 179–186.
Van Etten, R.A., Jackson, P.K., Baltimore, D., Sanders, M.C., Matsu-
daira, P.T., and Janmey, P.A. (1994). The COOH-terminus of the
c-Abl tyrosine kinase contains distinct F- and G-actin binding do-
mains with bundling activity. J. Cell Biol. 124, 325–340.
Vigneri, P., and Wang, J.Y. (2001). Induction of apoptosis in chronic
myelogenous leukemia cells through nuclear entrapment of BCR-
ABL tyrosine kinase. Nat. Med. 7, 228–234.
Walkenhorst, J., Goga, A., Witte, O.N., and Superti-Furga, G. (1996).
Analysis of human c-Abl tyrosine kinase activity and regulation in
S. pombe. Oncogene 12, 1513–1520.
Wang, J.Y.J. (1988). Negative regulation of c-abl tyrosine kinase by
its variable N-terminal amino acids. Oncogene Res. 3, 293–298.
Wang, J.Y. (2000). Regulation of cell death by the abl tyrosine kinase.
Oncogene 19, 5643–5650.
Woodring, P.J., Hunter, T., and Wang, J.Y. (2001). Inhibition of c-Abl
tyrosine kinase by filamentous-actin. J. Biol. Chem. 276, 27104–
27110.
